Abstract
Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.
Keywords: Sarcoma, biomarkers, FDA approved drugs, PI3K/Akt/mToR inhibitors, phytochemicals, nanomaterials.
Mini-Reviews in Medicinal Chemistry
Title:Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy
Volume: 24 Issue: 16
Author(s): Atif Khurshid Wani, Reena Singh, Nahid Akhtar, Ajit Prakash, Eugenie Nepovimova, Patrik Oleksak, Zofia Chrienova, Suliman Alomar, Chirag Chopra*Kamil Kuca*
Affiliation:
- School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
- Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia
- Biomedical Research Center, University Hospital Hradec Kralove, Hradec Králové, Czechia
Keywords: Sarcoma, biomarkers, FDA approved drugs, PI3K/Akt/mToR inhibitors, phytochemicals, nanomaterials.
Abstract: Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.
Export Options
About this article
Cite this article as:
Wani Atif Khurshid, Singh Reena, Akhtar Nahid, Prakash Ajit, Nepovimova Eugenie, Oleksak Patrik, Chrienova Zofia, Alomar Suliman, Chopra Chirag*, Kuca Kamil*, Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy, Mini-Reviews in Medicinal Chemistry 2024; 24 (16) . https://dx.doi.org/10.2174/0113895575270904231129062137
DOI https://dx.doi.org/10.2174/0113895575270904231129062137 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Drugs and mitochondria
Mitochondria play a central role in the life and death of cells. They are not merely the center for energy metabolism but are also the headquarters for different catabolic and anabolic processes, calcium fluxes, and various signaling pathways. Mitochondria maintain homeostasis in the cell by interacting with reactive oxygen-nitrogen species ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comparing India's Second COVID Wave with the First Wave-A
Single-Center Experience
Recent Advances in Anti-Infective Drug Discovery Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges
Current Medicinal Chemistry New and Old Hot Drug Targets in Tuberculosis
Current Medicinal Chemistry SARS-CoV-2 Therapy: Old Drugs as New Interventions
Coronaviruses Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Protein Domains as Information Processing Units
Current Protein & Peptide Science Antifungal Compounds from Piper Species
Current Bioactive Compounds Synthesis and Evaluation of New 5-methylisoxazole-3-carboxamide Derivatives as Antitubercular Agents
Anti-Infective Agents Impact of Covid-19 on Endometriosis Patients: An Integrative Review
Current Women`s Health Reviews A Simplified Framework for the Detection of Intracranial Hemorrhage in CT Brain Images Using Deep Learning
Current Medical Imaging Recent Topics in Organohalogen Reagents and Compounds
Current Organic Chemistry Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry An Overview of Recently Published Patents on Pulmonary Drug Delivery Devices
Recent Advances in Drug Delivery and Formulation Pilot Randomised Controlled Trial to Test Effectiveness of Facemasks in Preventing Influenza-like Illness Transmission among Australian Hajj Pilgrims in 2011
Infectious Disorders - Drug Targets Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors
Current Medicinal Chemistry Strategies in Medicinal Chemistry to Discover New Hit Compounds against Ebola Virus: Challenges and Perspectives in Drug Discovery
Mini-Reviews in Medicinal Chemistry The Emergence of Novel Coronavirus Disease, Global Treatment Update and its Containment Strategies in Overpopulated Countries: A Review
Coronaviruses Edema, Inflammation and Fibrosis – Comparison Between Catecholamine- and Hypoxia-Induced Pulmonary Injuries
Vascular Disease Prevention (Discontinued) SARS-CoV-2-Induced Neurological Disorders in Symptomatic Covid-19 and Long Covid Patients: Key Role of Brain Renin-Angiotensin System
Infectious Disorders - Drug Targets